ProQR Therapeutics (PRQR) News Today $1.99 -0.20 (-9.13%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.50%) As of 09/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $8.00 Consensus Price Target from Analysts5 hours ago | americanbankingnews.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Buy" from AnalystsSeptember 15 at 2:08 AM | marketbeat.comProQR Therapeutics N.V. $PRQR Shares Sold by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comHC Wainwright Expects Lower Earnings for ProQR TherapeuticsAugust 30, 2025 | marketbeat.comProQR Therapeutics N.V. $PRQR Shares Bought by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.com1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plcAugust 24, 2025 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comPRQR | ProQR Therapeutics N.V. Stock Price & News - WSJAugust 12, 2025 | wsj.comProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan CapitalAugust 9, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?August 8, 2025 | marketbeat.comProQR Announces Second Quarter 2025 Operating and Financial ResultsAugust 7, 2025 | globenewswire.comProQR Therapeutics (PRQR) Expected to Announce Earnings on ThursdayAugust 7, 2025 | marketbeat.comMonaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)July 30, 2025 | marketbeat.comProQR Announces Upcoming Presentation at RNA Editing SummitJuly 28, 2025 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by BrokeragesJuly 25, 2025 | marketbeat.comProQR Therapeutics price target raised to $5 from $4 at Evercore ISIJuly 12, 2025 | msn.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8, 2025 | investing.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's WhyJuly 8, 2025 | marketbeat.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from BrokeragesJune 30, 2025 | marketbeat.comProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comProQR Therapeutics N.V. (PRQR) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 27, 2025 | finanznachrichten.deProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP SecuritiesJune 27, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor FitzgeraldJune 27, 2025 | marketbeat.comProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 26, 2025 | globenewswire.comCantor Fitzgerald Comments on PRQR FY2026 EarningsJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)June 6, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by AnalystsJune 5, 2025 | marketbeat.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 2, 2025 | tipranks.comProQR Therapeutics (NASDAQ:PRQR) Short Interest Up 50.9% in MayJune 2, 2025 | marketbeat.comNorthern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)May 30, 2025 | marketbeat.comMillennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR)May 28, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 3,557,001 ProQR Therapeutics (NASDAQ:PRQR)May 25, 2025 | marketbeat.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comPoint72 Asset Management L.P. Takes Position in ProQR Therapeutics (NASDAQ:PRQR)May 22, 2025 | marketbeat.comFY2025 EPS Forecast for ProQR Therapeutics Cut by AnalystMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $602,000 in ProQR Therapeutics (NASDAQ:PRQR)May 16, 2025 | marketbeat.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from AnalystsMay 12, 2025 | marketbeat.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by DAFNA Capital Management LLCMay 10, 2025 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR Announces First Quarter 2025 Operating and Financial ResultsMay 8, 2025 | globenewswire.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼1.010.94▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼42▲PRQR Articles Average Week Get the Latest News and Ratings for PRQR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ProQR Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Spyre Therapeutics News Today ARS Pharmaceuticals News Today Praxis Precision Medicines News Today uniQure News Today atai Life Sciences News Today Cronos Group News Today CorMedix News Today Taysha Gene Therapies News Today Immunome News Today Amylyx Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
